MEA115921 (EGPA)

Full Name: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy
Study Dates: 2014-2017
NCT #: NCT02020889
Study Findings: Mepolizumab was shown to increase accrued time in remission, reduce frequency of relapse and exacerbation, and enable patients to reduce corticosteroid dose.